Related Experiment Video
Updated: Jun 17, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
2,3-Diaminopyrazines as Rho kinase inhibitors
Alan J Henderson1, Mark Hadden, Cheng Guo
1AMRI, 26 Corporate Circle, PO Box 15098, Albany, NY 12212-5098, USA. Alan.Henderson@amriglobal.com
Bioorganic & Medicinal Chemistry Letters
|December 22, 2009
Summary
Rho kinase (ROCK) inhibition is key for treating diseases like glaucoma. Researchers developed a novel ROCK inhibitor, compound 38, through structure-activity relationship studies and tested its efficacy in preclinical models.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Ophthalmology
Background:
- Rho kinase (ROCK) is a validated therapeutic target for various diseases.
- ROCK inhibition is particularly relevant for managing glaucoma.
Purpose of the Study:
- To report the structure-activity relationship (SAR) development of novel ROCK inhibitors.
- To introduce compound 38 as a potent ROCK inhibitor discovered through library screening.
- To evaluate the in vitro and in vivo efficacy of compound 38, including in a glaucoma model.
Main Methods:
- Screening of a kinase inhibitor library to identify initial hits.
- Structure-activity relationship (SAR) studies to optimize lead compounds.
- In vitro assays to assess ROCK inhibition.
- In vivo studies, including a non-human primate model of glaucoma, to evaluate compound 38's efficacy.
Main Results:
- Identification of two initial hits from kinase library screening.
- Optimization of hits through SAR studies led to the discovery of compound 38.
- Compound 38 demonstrated significant ROCK inhibitory activity.
- Preclinical data, including studies in a monkey model of glaucoma, supported compound 38's therapeutic potential.
Conclusions:
- Compound 38 is a novel and potent ROCK inhibitor.
- The developed compound shows promise for the treatment of glaucoma.
- Further investigation of compound 38 is warranted for clinical development.
Related Concept Videos
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...